FDA estimates that the aggregated net annualized costs of the rule, accounting for both losses and gains, will total $52.
The FDA predicts that the net cost will be $52.
delivery (called route time in U.S. delivery cost analyses),5 is accounted for by the need for the carrier to move from one stop6 to another whatever the mode of delivery.